Foghorn Therapeutics Inc.
FHTX · XNASCIK 1822462fmd_07D5G5359823ECN78GVW7RYY36Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2019 to Sep 30, 2026, 29 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Total revenues | – | 0 | 1 | 19 | 34 | 23 | 31 |
| Research and development | 44 | 58 | 80 | 106 | 110 | 95 | 85 |
| Total operating expenses | 51 | 69 | 102 | 136 | 142 | 125 | 117 |
| Operating income | (51) | (69) | (101) | (117) | (108) | (103) | (86) |
| Interest expense | 1 | 1 | 2 | – | – | – | – |
| Other non-operating income (expense) | (0) | (0) | (1) | 8 | 14 | 16 | 12 |
| Income before taxes | – | – | – | (109) | (94) | (87) | – |
| Income tax expense | 0 | 0 | – | 0 | 4 | 0 | 0 |
| Net income from continuing operations | – | – | – | (109) | (98) | (87) | – |
| Net income | (51) | (69) | (101) | (109) | (98) | (87) | (74) |